Clinical Trial Update: Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating selumetinib alone or with temsirolimus in patients with metastatic, recurrent, or locally advanced soft tissue sarcoma that cannot be r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Selumetinib (selumetinib)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2015-10-05